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Abstract: With the success of targeted monoclonal antibody therapy in non-Hodgkin’s lym-
phoma, attempts were made to further improve efﬁ  cacy through the addition of a radioisotope. 
A goal of radioimmunotherapy is to utilize the monoclonal antibody to deliver radiation to a 
tumor bed with relatively limited toxicity to the surrounding normal tissues. I-131 Tositumomab 
is an iodine-131 labeled anti-CD20 murine IgG2a monoclonal antibody and is one of two FDA-
approved radioimmunotherapeutic drugs for patients with non-Hodgkin’s lymphoma (NHL). For 
more than a decade now, radiolabeled tositumomab has principally been evaluated in low-grade 
and transformed low-grade NHL patients with proven efﬁ  cacy in both the up-front and salvage 
settings. Studies have included its use as a single agent, in combination with chemotherapy and 
as part of a conditioning regimen for autologous stem cell transplantation. These data suggest 
that this agent has an important role in the treatment of patients with B cell lymphoma.
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Introduction
The introduction of radioimmunotherapy into the management of B-cell non-Hodgkin’s 
lymphoma has shown substantial promise and clear patient beneﬁ  t. Early studies 
utilizing iodine-131-labeled tositumomab (Bexxar®, GlaxoSmithKline, Philadelphia, 
PA, USA) in the treatment of relapsed and refractory patients have shown durable 
responses, even in patients who have previously received chemotherapy and rituximab. 
More recent investigation has demonstrated that radiolabeled tositumomab has 
substantial activity in previously untreated patients, both as a single agent and in com-
bination with chemotherapy. Additionally, its use as part of a conditioning regimen for 
autologous stem cell transplantation has been examined. Altogether, the data suggest 
that radiolabeled tositumomab plays an important role in the management of patients 
with B-cell lymphoma.
Treatment regimen
The administration of tositumomab (unlabeled antibody) with iodine-131 tositumomab 
(labeled antibody) to patients involves a collaborative effort between the oncologist 
and the nuclear medicine or radiation oncology specialist. Patients receive on day 1 
outpatient doses of unlabeled and then trace-labeled tositumomab, followed by dosimet-
ric gamma camera scans at several time points over the next week. The data obtained 
allow the treating physician to determine the appropriate patient-speciﬁ  c activity of 
iodine-131 tositumomab to be administered a week later (in the therapeutic dose) in 
order to deliver a total body radiation exposure of 75 cGy. The dose is attenuated to 
65 cGy for patients with platelet counts between 100,000 and 150,000. Patients with 
cytopenias or extensive bone marrow inﬁ  ltration with lymphoma (greater than 25% Biologics: Targets & Therapy 2007:1(2) 114
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of intertrabecular space) are not candidates for radioim-
munotherapy due to excessive hematologic risk. Iodine 
supplementation is provided in the form of saturated solution 
of potassium iodide or Lugol’s solution to block the thyroid 
and limit toxicity. After the course of treatment is admin-
istered, patients are monitored for toxicity though periodic 
blood count and other laboratory tests, as well as response 
assessment through standard imaging.
Early studies
In 1993, Kaminski, Wahl and colleagues from the University of 
Michigan published phase I data on 10 patients with relapsed 
or refractory non-Hodgkin’s lymphoma (NHL) (Kaminski 
et al 1993). Half the patients had low grade (indolent) lym-
phoma and the other half had intermediate-grade (aggres-
sive) lymphoma. Following the administration of unlabeled 
antibody, radioimmunotherapy escalating whole-body expo-
sures starting at 25 cGy and increasing by 10 cGy increments 
were given until a maximal tolerated dose not requiring stem 
cell support was determined. Out of nine evaluable patients, 
6 responded (4 CR [complete remission], 2 partial remission 
[PR]). All four patients with CR entered remission with only 
one course of radiotherapeutic drug. Remissions lasted 8–11 
months. Minimal toxicity was observed, the most common of 
which was reversible myelosuppression. These early ﬁ  ndings 
of meaningful responses in previously treatment-refractory 
patients led to the acceleration of further early phase test-
ing which established 75 cGy as the maximally tolerated 
whole-body radiation dose of 131I-labeled-anti-CD20 antibody 
(Kaminski et al 1996). This early work paved the way for 
further development of radiolabeled tositumomab in NHL.
Single-agent radiolabeled 
tositumomab in relapsed/refractory 
NHL
Two US-based phase II clinical trials have examined the 
efﬁ  cacy of iodine-131 tositumomab in heavily pretreated 
low-grade and transformed NHL patients (Kaminski et al 
2000; Vose et al 2000, Table 1). In 2000, Vose and col-
leagues published a multicenter phase II study of radiolabeled 
tositumomab in patients with chemotherapy-relapsed and 
chemotherapy–refractory low-grade or transformed NHL.
The principal goal of this study was to expand the use 
of this agent into multiple centers beyond the University of 
Michigan and to assess its utility more broadly. This popula-
tion of patients in this trial was heavily pre-treated having 
received a median of 4 prior chemotherapeutic regimens. 
Furthermore, more than half of the 45 patients were refractory 
to their most recent lymphoma therapy. Despite these adverse 
prognostic features, the administration of radiolabeled tosi-
tumomab to this group resulted in a 57% overall response 
(32% CR). Importantly, responses were observed in both 
the low-grade (indolent) and transformed NHL patients. 
The median overall response duration was 9.9 months and 
for those who achieved a CR, their median response dura-
tion was double (19.9 months). Principal toxicities, as in the 
phase I studies, were hematologic.
This multicenter experience conﬁ  rmed the single-center 
ﬁ  ndings from a phase I/II trial of single-agent radiolabeled 
tositumomab published in the same year by Kaminski 
et al (2000). As in the multicenter study, nearly half of 
the 59 patients were refractory to their most recent che-
motherapeutic regimen. Likewise, comparable complete 
remission rates (34%) and median progression-free surviv-
als (12 months) were observed. Long-term adverse effects 
included asymptomatic TSH elevations in 5 patients, a 
diagnosis of myelodysplasia (MDS) or acute myelogenous 
leukemia (AML in 5 patients, and 3 patients with the devel-
opment of solid tumors (2 transitional cell bladder cancer 
and 1 with squamous cell carcinoma of the anus). Nearly all 
patients who developed subsequent malignancies had been 
exposed to known predisposing chemotherapeutic agents (eg, 
alkylating agents and cyclophosphamide) prior to receiving 
radioimmunotherapy, making the role of prior chemotherapy 
versus that of radioimmunotherapy unclear with respect to 
the etiology of late toxicity.
Collectively, these two studies demonstrated that treat-
ment-refractory patients who had undergone a median of 
3 or 4 prior therapies were still able to respond to radiola-
beled tositumomab. Additionally, a UK-based phase II study 
(Davies et al 2004, Table 1) sought to examine the efﬁ  cacy 
of radiolabeled tositumomab earlier in the disease course, 
at the ﬁ  rst or second relapse. As expected, the subjects were 
overall more favorable than in the multiply-relapsed patients 
in the Kaminiski and Vose studies with the majority of the 
subjects having low-risk International Prognostic Index 
scores and two-thirds having only received one prior chemo-
therapeutic treatment. A similar overall response rate of 76% 
was observed; however, a higher complete remission rate of 
nearly 50% was obtained with an overall median remission 
duration of 1.3 years. These data suggest that perhaps more 
and lengthier complete remissions could be obtained by 
administration of radiolabeled tositumomab earlier in the 
natural history of the disease.
Altogether, these phase II publications suggest that 
radiolabeled tositumomab can produce responses both in Biologics: Targets & Therapy 2007:1(2) 115
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patients with a ﬁ  rst or second relapse, but also in the treat-
ment-refractory and multiply-relapsed setting.
In light of the now ubiquitous use of the anti-CD20 
monoclonal antibody rituximab in the treatment of B-cell 
lymphomas, a key issue became the utility of anti-CD20 
radioimmunotherapy in patients who had previously been 
treated with an unlabeled agent with the same target. Horning 
and colleagues published an important prospective phase II 
study examining the efﬁ  cacy of radiolabeled tositumomab in 
patients who had progressed after rituximab therapy (Horning 
et al 2005, Table 1). Forty follicular or transformed follicular 
NHL patients who had received a median of 4 prior treatment 
regimens were studied. Thirty-ﬁ  ve of patients had no response 
or a response duration of less than 6 months to prior rituximab 
and therefore are considered to be rituximab-refractory by 
standardly accepted criteria. Treatment of these subjects with 
radiolabeled tositumomab generated a 65% overall response 
(38% CR) and a 10.4 month progression-free survival (PFS) at 
3.3 years of median follow up. Overall response rate, duration 
of response and median PFS were unchanged by stratiﬁ  ca-
tion for prior response to rituximab. Importantly, this work 
demonstrated a role for radiolabeled tositumomab in patients 
who had progressed after treatment with rituximab, regardless 
of their previous response to it.
A pivotal phase III study of single-agent tositumomab in 
refractory NHL has also been conducteded (Kaminski et al 
2001, Table 1) that by design assessed its activity in the che-
motherapy-refractory patient population. This multicenter trial 
of 60 chemotherapy-refractory low-grade or transformed low-
grade (indolent) lymphoma patients was conducted in a non-
randomized fashion with comparisons being made to enrolled 
patients’ responses to their last qualifying chemotherapy (LQC) 
regimen. The overall response rate was 65% (20% CR) and was 
statistically better than the overall response to the LQC. Simi-
larly, the complete remission rate was signiﬁ  cantly higher (3% 
vs 20%, p < 0.001) and the median response duration nearly 
doubled (6.5 vs 3.4 months, p < 0.001) in comparison to the 
prior chemotherapy. The non-randomized (patient as their own 
control) nature of the study poses potential biases, however, 
a chemotherapy control arm would be impractical given the 
heterogeneity of the patient population. These data suggest that 
radioimmunotherapy can reverse the trend of shorter remissions 
with each sequential therapy that has been well-reported in 
indolent lymphoma (Johnson et al 1995).
A larger integrated efﬁ  cacy analysis of 250 patients with 
relapsed or refractory low-grade and transformed NHL who 
were treated with a single course of radiolabeled tositumomab 
demonstrated high response rates (47%–68%) that were 
durable (> 1 year) in one third of patients (Fisher et al 2005). 
Within this durable response population, 77% achieved a CR 
and 23% a PR. With a median follow-up of 5 years, the PFS 
for those who had achieved a CR had not yet been reached. 
The fact that patients with recurrent/resistant disease can have 
durable remissions with radioimmunotherapy is important in 
establishing its value. It was this data set that formed the basis 
of the 2003 regulatory approval of iodine-131 tositumomab 
by the US Food and Drug Administration for the treatment 
of patients with CD20 positive, follicular, NHL, with and 
without transformation, whose disease is refractory to ritux-
imab and has relapsed following chemotherapy.
Single-agent radiolabeled 
tositumomab in untreated 
follicular NHL
Given the high response rates observed in refractory patients, 
several investigators sought to study the efﬁ  cacy of tositu-
momab as initial therapy in advanced stage follicular lym-
phoma (Kaminski et al 2005a, Table 1). A single therapeutic 
dose of tositumomab was administered by Kaminski and 
colleagues to 76 patients of which 95% had a response (75% 
CR). With a median follow-up of 5.1 years, the actuarial 5-year 
PFS was 59% with median PFS of 6.1 years. The 5-year rate of 
overall survival was 89%. Follicular Lymphoma International 
Prognostic Index (FLIPI) score was not predictive of overall 
response or PFS; however an overall survival difference was 
observed when low- and intermediate-risk patients were com-
pared with high risk patients. These data may suggest that the 
beneﬁ  t of up-front treatment with radiolabeled tositumomab 
may be more useful in the lower-risk IPI patients and perhaps 
should be considered as initial therapy speciﬁ  cally for such 
patients. This landmark trial demonstrated that one course of 
treatment (over one week) with radiolabeled tositumomab can 
produce durable remissions in previously untreated patients 
with advanced follicular lymphoma. What remains to be seen 
is how this treatment regimen compares in the long term (with 
respect to efﬁ  cacy and toxicity) to other commonly employed 
regimens such as chemotherapy plus rituximab.
Radiolabeled tositumomab 
in combination with chemotherapy
The Southwest Oncology Group (SWOG) performed a phase II 
trial studying the combined effect of CHOP followed by radio-
labeled tositumomab in 90 previously untreated, advanced stage 
follicular lymphoma patients (Press et al 2006, Table 2). The 
treatment course consisted of standard CHOP chemotherapy Biologics: Targets & Therapy 2007:1(2) 117
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every 21 days for 6 cycles. Patients who received at least a 
partial response to CHOP were then consolidated with radiola-
bleled tositumomab 4–8 weeks later. Ninety percent achieved 
remission (69%CR, 23%PR). The 5-year overall survival rate 
for patients in this study was 87% and PFS rate was 67%. 
Comparing outcomes with historical CHOP alone data from 
SWOG (Dana et al 1993), CHOP plus radiolabeled tositumomab 
demonstrated a 23% higher estimated 5-year PFS (67% vs 44%, 
p = 0.001) and overall survival (87% vs 64%, p = 0.0003). These 
data are particularly impressive, given the fact that they were 
obtained in a cooperative group, community-based setting, 
rather than a single institution trial. These ﬁ  ndings have led to 
an intergroup, randomized trial of CHOP-tositumomab versus 
CHOP-rituximab in previously untreated follicular lymphoma 
patients.
Our own group has also examined radiolabeled tositu-
momab in combination with chemotherapy (Leonard et al 
2005, Table 2). We conducted a phase II, single-institution 
study of 35 previously untreated follicular lymphoma patients 
given an abbreviated course of ﬂ  udarabine (three cycles) fol-
lowed six to eight weeks later by radiolabeled tositumomab. 
The patients generally had high risk disease (45% with high 
risk FLIPI). The overall response rate after completing ﬂ  uda-
rabine was 89% (9% CR). However, after completion of the 
entire regimen (ﬂ  udarabine + radiolabeled tositumomab) the 
overall response was 100% with 86% of patients achieving a 
complete remission. After a median follow up of 58 months, 
the median response duration and median progression free 
survival had not yet been reached suggesting durable responses 
are possible with this regimen.
We have additionally evaluated CVP chemotherapy fol-
lowed by radiolabeled tositumomab in untreated follicular 
lymphoma (Link et al 2004). All enrolled patients (n = 30) 
completed full therapy. This regimen produced an overall 
response rate of 100% and a CR rate of 80%. Among patients 
who achieved less than a CR with CVP, 60% achieved a CR 
after radioimmunotherapy. With a median follow-up of 2.3 
years, 77% of patients continued in response. This study sug-
gests that the combination of CVP + radiolabeled tositumomab 
is a promising therapeutic regimen for patients with previously 
untreated, advanced-stage, follicular NHL.
The results of these trials combining standard chemo-
therapy with radioimmunotherapy as up-front therapy in 
follicular lymphoma patients suggest that partial tumor 
reduction by chemotherapy may be converted to complete 
and durable responses by the subsequent administration of 
radioimmunotherapy. However, it remains to be seen whether 
the addition of chemotherapy to radioimmunotherapy has any 
advantage over radioimmunotherapy alone. A randomized 
trial of chemotherapy + radioimmunotherapy versus radioim-
munotherapy would be ideal to answer this question. In the 
meantime, the SWOG and CALGB (Cancer and Leukemia 
Group B) are conducting a randomized study in of CHOP 
+ concurrent rituximab vs CHOP followed by I-131 tositu-
momab in order to assess the role of radioimmunotherapy as 
part of initial treatment in follicular lymphoma.
Radiolabeled tositumomab 
in autologous stem cell 
transplantation
A commonly used conditioning regimen for relapsed lym-
phoma patients undergoing autologous stem cell transplanta-
tion (ASCT) includes total body irradiation (TBI) followed 
Table 2 Tositumomab in combination with chemotherapy 
Author Study  design  Patient  Overall  Median  Median Median  MDS  HAMA
   population  response  PFS  CR  survival     
Press    Phase II  Previously   91% OR  5 year est     5 year est   1.1% Not 
et al 2003,   SWOG 9911  untreated   (69% CR)  PFS 67%   OS  87%   reported
2006 CHOP+tositumomab  follicular NHL            
   (n  = 90)           
   21% high-risk            
   FLIPI          
Leonard  Phase II  Previously   100% OR  Not       One   6%
et al   Single institution  untreated FL     reached at      patient  
2005 Open  label  patients  86% CR   median       developed 
  Prospective      follow up        MDS at  
  3 cycles of       of 58       58  
  ﬂ  udarabine followed      months      months  
 by  tositumomab           post-therapy 
Abbreviations: CR, complete remission; FLIPI, Follicular Lymphoma International Prognostic Index; HAMA, human anti-mouse antibody formation; NHL, non-Hodgkin’s 
lymphoma; OR, odds ratio; PFS, progression-free survival; MDS, development of myelodysplasia.Biologics: Targets & Therapy 2007:1(2) 118
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by high dose chemotherapy. Although TBI is efﬁ  cacious as a 
preparative regimen, its organ toxicity in addition to myelo-
toxicity is a major limitation. Several groups have sought to 
limit the toxicity of TBI, or enhance its efﬁ  cacy, by replacing 
it with radioimmunotherapy (RIT). The rationale for this 
approach is that targeted delivery of radiation preferentially 
to lymphoma sites might enable physicians to give higher 
dose of radiation without undue toxicity to normal body sites 
and perhaps increase the number and durability of remissions 
from ASCT.
In 2000, Press and colleagues evaluated radiolabeled 
tositumomab administered in conjunction with 60 mg/kg 
of etoposide and 100 mg/kg of cyclophosphamide fol-
lowed by ASCT (Press et al 2000, Table 3). Fifteen percent 
of patients experienced grade III or IV toxic effects. All 
four treatment-related deaths were due to opportunistic 
infections. Compared with non-randomized controls who 
received TBI in combination with etoposide and cyclo-
phosphamide, patients who received radioimmunotherapy 
as part of their preparative regimen had higher overall and 
PFS, suggesting a beneﬁ  t overall to the use of RIT. This 
group also examined high-dose chemo-radioimmuno-
therapy (HD-RIT) followed by ASCT in relapsed mantle 
cell lymphoma patients (Gopal et al 2002, Table 3). They 
observed an estimated 3-year overall survival and PFS of 
93% and 61%, respectively. These responses were observed 
even in patients with chemo-refractory disease, suggesting 
that high dose iodine-131 tositumomab (with or without 
chemotherapy) with stem cell support may be a valuable 
treatment strategy in some settings.
Vose and colleagues examined the combination of radio-
labled tositumomab with high-dose carmustine, etoposide, 
cytarabine and melphalan (BEAM) followed by ASCT 
in chemotherapy-refractory of multiply-relapsed B-cell 
NHL patients (Vose et al 2005, Table 3). Overall survival 
and PFS at 2 years was 83% and 68%, respectively. Time 
to engraftment and non-hematologic toxicity was similar 
to historical control patients receiving BEAM alone. The 
maximum tolerated dose of radiolabeled tositumomab was 
higher in this phase I study at 75 cGy total body dose. This 
suggests that radioimmunotherapy can be given in combina-
tion with chemotherapy prior to ASCT and that tolerability 
is largely dependent upon the toxicities of the chemothera-
peutic component of the conditioning regimen.
A comparison of over 100 consecutive follicular 
lymphoma patients who underwent autologous stem cell 
transplantation with either HD-RIT using radiolabeled tosi-
tumomab or conventional high-dose therapy suggested that 
HD-RIT patients experienced a signiﬁ  cant improvement in 
overall survival and PFS (Gopal et al 2003). However, a 
Table 3 Tositumomab prior to autologous stem cell transplantation 
Author Study  Patient  Overall  Median  Median Median  MDS  HAMA 
 design  population  response  PFS  CR  survival   
Press et   Phase I/II  Relapsed (n = 55)  87% 68% PFS     83% OS   1.9% 15%
al 2000  Tositumomab  Follicular gr I/II     at 2 years    at 2 years   
  +chemo prior    (n = 34)           
  to ASCT  Follicular grade III            
   (n  = 4)           
    Mantle cell (n = 6)           
   Transformed  (n  = 6)           
    De novo DLBCL            
   (n  = 2)           
Gopal et   Retrospective  Relapsed/refractory  100%   61%     93%   Not   Not 
al 2002  Tositumomab    Mantle cell (n = 16)  (91% CR)  estimated     estimated   reported  reported
  + chemo prior       3 year PFS    3 year OS   
 to  ASCT           
Vose et   Phase I  23 chemotherapy   65% OR      OS 55%   2 out of   35%
al 2005  Tositumomab +   refractory or   (57% CR)      at 38   23  
  high dose   multiply relapsed         months of  (median 
  BEAM followed   B-cell NHL          follow up   f/u 38  
 by  ASCT patients         months) 
   61% DLBCL, 17%          
     follicular grade 3,            
   22% mantle cell           
Abbreviations: ASCT, autologous stem cell transplantation; CR, complete remission; DLBCL, diffuse large B-cell lymphoma; HAMA, human anti-mouse antibody formation; 
NHL, non-Hodgkin’s lymphoma; OR, odds ratio; OS, overall survival; PFS, progression-free survival; MDS, development of myelodysplasia;.Biologics: Targets & Therapy 2007:1(2) 119
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randomized comparison of TBI versus radioimmunotherapy 
is obligatory to determine differences, if any, in efﬁ  cacy and 
toxicity. Currently, the Blood and Marrow Transplant Clini-
cal Trials Network (BMT CTN) is conducting a phase III, 
multi-center trial comparing progression-free survival after 
autologous hematopoietic stem cell transplantation using a 
standard rituximab plus BEAM transplant regimen versus 
a regimen adding radiolabeled tositumomab to BEAM in 
patients that have persistent or recurrent diffuse large B-cell 
lymphoma.
Re-treatment with tositumomab
Given previously observed response durability in subsets 
of patients who had received radiolabeled tositumomab, 
the question of whether re-treatment with this agent could 
produce a second and safe response upon disease progres-
sion in some patients. To address this question, 32 patients 
with low-grade, follicular, or transformed low-grade B-cell 
lymphoma who relapsed after a response to radiolabeled 
tositumomab (and who recovered hematologic parameters) 
were enrolled into a phase II single-arm, open-label, multi-
center study (Kaminski et al 2005b). Patients were required 
to have achieved at least a partial response for a duration of 
at least three months following initial treatment radioim-
munotherapy. The majority of patients (84%) had low grade 
follicular lymphoma. The subjects had received a median of 
4 previous treatments and 22% of the patients had received 
rituximab. Overall response was 56% (25% with CR or 
clinical complete response) with an overall median response 
duration of 15.2 months. There was no signiﬁ  cant difference 
in median duration of ﬁ  rst and second response and toxic-
ity was comparable to that observed after initial therapy. 
Altogether, this study showed that patients who relapse fol-
lowing an initial response to tositumomab can have a second 
response that is as durable with acceptable toxicity. Patient 
selection, based on hematologic reserve and effectiveness of 
the prior course of radioimmunotherapy, may be important 
in optimizing the use of retreatment.
Toxicities
The adverse-effect proﬁ  le of tositumomab use includes grade 
IV cytopenias (minority of patients), rare but serious and even 
fatal hypersensitivity reactions, hypothyroidism, the develop-
ment of human-antimouse antibodies (HAMA), and second-
ary malignancy. Infusion of tositumomab must be done under 
conditions in which treatment for anaphylaxis can be initiated 
promptly. Administration of potassium iodide is implemented 
prior to and after treatment to reduce the incidence of second-
ary hypothyroidism. The development of HAMA appears 
to be related to the degree of immunosuppression. Patients 
who have undergone prior treatment with chemotherapy 
tend to have low rate of HAMA development which is often 
clinically undetectable (only on blood serology) (Table 1), 
whereas patients treated with tositumomab in the ﬁ  rst-line 
setting developed HAMA in 63% of cases.
The most concerning of the toxicities related to the admin-
istration of tositumomab is the potential for the development 
of secondary malignancy, most notably MDS and AML. 
Secondary MDS and AML have long been recognized as 
potential complications of treatment for NHL even before 
the era of radioimmunotherapy (Armitage et al 2003). With 
the prolonged survival observed in patients treated with 
tositumomab, it is unclear whether the development of sub-
sequent MDS/AML is related to the radioimmunotherapy 
or to the longer period of observation after chemotherapy 
in patients who are living longer. Bennett and colleagues 
examined this question in a review of 1071 patients treated 
with radiolabeled tositumomab (Bennett et al 2005). A 6.3% 
5-year cumulative incidence of MDS/AML was observed 
in patients who received radiolabeled tositumomab in the 
relapsed/refractory setting. However, with a median fol-
low up of 5 years, no cases of MDS/AML were observed 
in patients who received tositumomab as initial therapy. 
Longer follow up is needed, but these initial data suggest 
that radiolabeled tositumomab is safe and that the develop-
ment of secondary MDS/AML may be attributable to both 
the duration and amount of prior chemotherapy as well as 
to effects of the radioimmunotherapy itself.
Conclusions
The last decade has seen much investigation into the role of 
radioimmunotherapy in the treatment of NHL. Radiolabeled 
tositumomab clearly is able to produce durable and lengthy 
complete remissions with progression-free and overall-sur-
vival beneﬁ  ts in relapsed and treatment-refractory patients, 
including those who have progressed after rituximab. This 
suggests that it may be utilized as a way to overcome resis-
tance or to get lengthier remissions in patients with respon-
sive disease but short prior remissions. Its role in the up-front 
setting is promising although comparisons to alternative 
regimens are awaited. Whether I-131 tositumomab should be 
used as a single-agent or in combination with chemotherapy 
needs to be further studied. Challenges in understanding the 
role of radioimmunotherapy in NHL are the lack of random-
ized data and unclear comparisons to other agents. Additional 
questions relate to the integration of radioimmunotherapy Biologics: Targets & Therapy 2007:1(2) 120
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with other approaches, and whether it should be used early 
in the course of the disease, at ﬁ  rst or second relapse, or later 
once resistance to other drugs has emerged. Further investiga-
tion in the form of randomized control trials will hopefully 
clarify the role of radioimmunotherapy in the management 
of patients with NHL.
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